吉非替尼一线治疗老年晚期非小细胞肺癌患者的临床评价

Clinical value of geftinat on first line treatment in old age advanced NSCLC

关键词:  肺肿瘤  表皮生长因子受体  吉非替尼

Key words:  lung neoplasms/therapy  epidermal growth factor receptor  geftinat

摘要:

［目的］观察吉非替尼一线治疗老年晚期非小细胞肺癌患者的临床疗效及不良反应。［方法］ 收集大连医科大学附属第二医院肿瘤科2005年11月~2007年9月16例一线口服吉非替尼治疗的老年晚期非小细胞肺癌患者的临床资料，评价其疗效及不良反应。［结果］16例患者中完全缓解（CR）0%(0/16)，部分缓解(PR)37.5%（6/16），稳定(SD)50%（8/16），进展（PD）12.5%(2/16)。疾病控制率87.5%（14/16）。不良反应：皮疹 37.5%（6/16），皮肤干燥脱屑：18.75%（3/16），皮肤瘙痒12.5%（2/16），腹泻31.25%(5/16 )，转氨酶升高12.5%（2/16）。［结论］吉非替尼一线治疗老年晚期非小细胞肺癌疗效较好，不良反应轻微，有明显改善患者生活质量的趋势。

Abstract:

［Objective］To evaluate the response and the side effects of geftinat on the first line treatment in old age advanced stage non-small cell lung cancer.［Methods］Fourteen non-small cell lung cancer patients, the date of patients belong to the second affiliated hospital of dalian medical university, November 2005 to May 2007.iressa was prescribed on the first line at oral dose of 250mg daily as a continuous dose, Then To evaluate the response and side-effects of geftinat.［Results］Among 16 patients, CR, PR, SD,PD were 0%(0/16),37.5%（6/16）,50%（8/16）,12.5%(2/16). CR+PR+SD 87.5%（14/16）.Adverse events: rash 37.5%（6/16）,dry skin 18.75%（3/16）, itching of skin 12.5%（2/16）,diarrhea 31.25%(5/16) ,and hepatic dysfunction (GPT increase) 12.5%（2/16）.［Conclusion］Geftinat is active on the first line treatment in old age advanced stage non-small cell lung cancer. It is well tolerated with adverse events. The quality of the life may be improved significantly.